DUBLIN–(BUSINESS WIRE)–The “Cardiomyopathies Market Size and Trend Report together with Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031” drug pipelines has been added to ResearchAndMarkets.com’s providing.
The writer initiatives the therapeutic marketplace for cardiomyopathies inside the 7MM will develop from $1.6B in 2021 at a compound annual progress price (CAGR) of 12.4% to $5.2B by 2031.
Companies Mentioned
AstraZeneca
Merck
Boehringer Ingelheim
Novartis
Sanofi
Abbott
GlaxoSmithKline
Bristol Myers Squibb
MyoKardia
Pfizer
Cytokinetics
Main drivers of progress:
Camzyos (Bristol Myers Squibb) and aficamten (Cytokinetics) launch throughout the 7MM
Entresto (sacubitril + valsartan) label growth to embrace CM
Key Highlights
The cardiomyopathies market is at the moment extremely genericized and accommodates many off-label drugs, which offer reasonably priced choices with restricted unwanted effects. These elements create a stiff barrier for entry of novel therapeutics, however pipeline therapeutics will discover success due to robust efficacy and security profiles and that they’re cardiomyopathy-particular therapeutics, reasonably than basic cardiovascular medication.
There is an elevated deal with genetic screening and growing genetic therapeutics as a result of cardiomyopathies are sometimes inherited reasonably than acquired. Emprumapimod would be the first marketed genetic remedy, because it targets sufferers with DCM due to a lamin gene mutation. However, this drug won’t generate vital income given the small dimension of the goal affected person inhabitants.
There will not be a treatment for cardiomyopathies, as an alternative the illness signs are managed with generic cardiovascular medication. This stays an space of unmet want within the cardiomyopathies area.
Camzyos was the primary novel remedy launched within the cardiomyopathies market in a number of many years when it was marketed in 2022. Thus, there’s a want for novel therapies on this area, which must be met by the intensive pipeline.
Scope
Overview of cardiomyopathies together with epidemiology, illness etiology and administration.
Topline cardiomyopathy medication market income (together with off-label adjunct therapeutics used for metabolic advantages), annual value of remedy, and anticipated gross sales for main late-stage pipeline medication.
Key subjects lined embrace evaluation of present and pipeline therapies, unmet wants, present and future gamers and market outlook for the US, 5EU, and Japan over the ten-yr forecast interval.
Pipeline evaluation: Emerging novel traits beneath improvement, and detailed evaluation of late-stage pipeline medication.
Analysis of the present and future market competitors within the international cardiomyopathy therapeutics market. Insightful assessment of the important thing trade drivers, restraints and challenges.
Reasons to Buy
The report will allow you to:
Develop and design your in-licensing and out-licensing methods, utilizing an in depth overview of present pipeline merchandise and applied sciences to establish corporations with probably the most strong pipelines.
Develop enterprise methods by understanding the traits shaping and driving the worldwide cardiomyopathy therapeutics market.
Drive revenues by understanding the important thing traits, revolutionary merchandise and applied sciences, market segments, and corporations probably to affect the worldwide cardiomyopathies market sooner or later.
Formulate efficient gross sales and advertising methods by understanding the aggressive panorama and by analyzing the efficiency of assorted opponents.
Identify rising gamers with probably robust product portfolios and create efficient counter-methods to achieve a aggressive benefit.
Track drug gross sales within the international cardiomyopathy therapeutics market from 2021-2031.
Organize your gross sales and advertising efforts by figuring out the market classes and segments that current most alternatives for consolidations, investments and strategic partnerships.
Key Topics Covered:
1 Cardiomyopathies: Executive Summary
2 Introduction
3 Disease Overview
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
4 Epidemiology
4.1 Disease Background
4.1.1 Risk Factors and Comorbidities
4.2 Global and Historical Trends
4.3 Forecast Methodology
4.4 Epidemiological Forecast for Cardiomyopathies (2021-2031)
4.5 Discussion
5 Disease Management
5.1 Diagnosis and remedy overview
5.2 KOL insights on illness administration
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Improvements in genetic screening and gene therapies
7.3 Curative reasonably than preventative remedy choices
7.4 Newer medication with particular targets
7.5 Adequate analysis and remedy of amyloid cardiomyopathy sufferers
8 R&D Strategies
8.1 Overview
8.1.1 Label growth
8.1.2 Development of medication with novel targets
8.2 Clinical trial design
8.2.1 Quality of life endpoints
9 Pipeline Assessment
9.1 Overview
9.2 Promising medication in medical improvement
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive evaluation
11 Current and Future Players
11.1 Overview
11.2 Deal-making traits
12 Market Outlook
13 Appendix
For extra details about this drug pipelines report go to https://www.researchandmarkets.com/r/51ty3v
Source: GlobalKnowledge
https://news.google.com/__i/rss/rd/articles/CBMixQFodHRwczovL3d3dy5idXNpbmVzc3dpcmUuY29tL25ld3MvaG9tZS8yMDIyMTEyMzAwNTQxNC9lbi9HbG9iYWwtQ2FyZGlvbXlvcGF0aGllcy1NYXJrZXQtUmVwb3J0LXRvLTIwMzEtLS1GZWF0dXJpbmctQXN0cmFaZW5lY2EtTWVyY2stTm92YXJ0aXMtU2Fub2ZpLWFuZC1BYmJvdHQtQW1vbmctT3RoZXJzLS0tUmVzZWFyY2hBbmRNYXJrZXRzLmNvbdIBAA?oc=5
